6 results about "SOX9" patented technology

The present application provides SOX9 inhibitor compounds and compositions and methods of use thereof. In certain aspects, the SOX9 inhibitor is a peptide comprising a portion of the SOX9 dimerization motif. In other aspects, the SOX9 inhibitor is a compound of the general formula Iwhere one A is H and the other is:and the remaining substituents are as defined in the application.

The present invention discloses the use of Avn Anthramides C (Avn C) as an inducer of chondrocytic differentiation in Mesenchymal Stem Cells (MSCs), providing a promising approach for regenerative cartilage therapy. By employing Avn C treatment, MSCs exhibit enhanced chondrocytic differentiation and elevated expression of key specific chondrogenic extracellular matrix (ECM) factors, notably Collagen Type II (COL2A1). Furthermore, when Avn C is used in combination with Chondroitin Sulfate (CS), a synergistic effect is observed, leading to upregulation of the transcriptional activity state of SOX9, a key regulator of chondrogenesis. The disclosed invention shows significant improvements in mRNA gene expression (ACAN, LRP1, SOX9), cellular protein levels (COL2A1, SOX9, LRP1), and functional outcomes, as evidenced by the secretion of extracellular matrix proteins (FSTL-1, BGH3, CO1A1, CO1A2, and CO3A1).

Provided herein is a differentiation agent that consists essentially of SOX9 for the production of oligodendrocyte progenitor cells (OPCs) from pluripotent stem cells (PSCs). Also provided herein are methods of producing the PSCs and methods of using the PSCs to produce OPCs and oligodendrocytes.

A method of differentiating nonhuman primate induced pluripotent stem cells (iPSCs) into astrocytes may include providing a modified vector comprising a piggyBac vector backbone configured to express SOX9 and NFIB. The piggyBac vector backbone may include terminal inverted repeats and transposase recognition sites that support stable genomic integration of the inserted differentiation factor genes. Introduction of the vector into nonhuman primate iPSCs, such as Macaca fascicularis iPSCs, may initiate transcriptional programs associated with astrocyte-lineage commitment and maturation. Expression of SOX9 and NFIB may facilitate the formation of astrocytic morphology and the development of molecular features associated with astrocytes, including process elaboration and lineage-specific marker expression. The method may further include culturing the transfected cells under conditions that support astrocytic differentiation and expansion, resulting in populations of astrocytes or induced astrocytes suitable for research, disease modeling, and / or therapeutic applications.

The application relates to the field of biomedical technology, and particularly discloses application of an exosome overexpressing CAP and LGR5 genes in preparation of a drug for treating cartilage inflammation. The exosome overexpressing the CAP and LGR5 genes has both targeting property and cartilage protection function, the exosome can be more phagocytosed by cartilage cells, is targeted to the cartilage cells, can improve the levels of a cartilage generation gene Col2a1 and a cartilage development regulating gene Sox9, can reduce the level of a cartilage degradation gene Mmp13, can relieve cartilage abrasion of osteoarthritis mice, and can protect knee joints, so that the exosome can promote cartilage generation, relieve cartilage aging and reduce cartilage degradation under a complex inflammation environment. Further, the application provides a mesenchymal stem cell exosome overexpressing CAP / LGR5, provides a new technical scheme for targeted treatment based on stem cell engineering, and has a wide application prospect.